Please login to the form below

Not currently logged in
Email:
Password:

decitabine

This page shows the latest decitabine news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Pfizer gets first FDA nod for hedgehog inhibitor in AML

And in a bumper day for the therapeutic category, the FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethyelating agent (azacitidine or decitabine) for the exact

Latest news

  • Otsuka to buy cancer biopharma Astex Otsuka to buy cancer biopharma Astex

    Astex' lead product is Dacogen (decitabine), which is approved for the treatment of myelodysplastic syndromes and for acute myeloid leukaemia (AML) in patients over 65 years of age.

  • Cancer data presented at ASCO

    Elsewhere, Eisai presented data concerning a phase III study of DNA methylation inhibitor Dacogen (decitabine) for injection in acute myeloid leukaemia (AML).

  • J&J positive about pipeline

    this month; and Dacogen (decitabine), currently sold as a treatment for myelodysplastic syndromes, for the new indication of acute myeloid leukaemia.

  • The Pump House

    RECENTLY LAUNCHED products. Generic name. Trade name (company). Indication. Country. Decitabine.

  • Eisai acquires MGI Pharma for USD 3.9bn

    With a focus on cancer, MGI Pharma has three marketed products: Dacogen (decitabine) for myelodysplastic syndrome; Gliadel wafers (polifeprosan 20 with carmustine implant) for the treatment of brain cancers; and the

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient

  • Pharma deals during September 2013 Pharma deals during September 2013

    Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...
Fearless Girl cover
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)...

Infographics